Prince Mario-Max Schaumburg-Lippe: One Monthly Shot Changes Life With Schizophrenia

Imagine a medicine that works but only if you take it perfectly, every single day, for the rest of your life. One missed pill can spiral into a crisis. That has been the quiet trap inside schizophrenia care for decades. On Friday, October 9, the FDA approved something that breaks the trap: WELTRUZA, a once-a-month shot from Teva Pharmaceuticals. One subcutaneous injection, and the medicine holds for a month.

Olanzapine has been a foundational schizophrenia treatment for more than 30 years. It is the most widely prescribed atypical antipsychotic for the condition. But the daily-pill arrangement is fragile. Roughly 2.8 million adults in the United States live with schizophrenia, and surveys of clinicians consistently rank adherence among the top drivers of relapse – and relapse can mean emergency visits, hospital stays, lost jobs, strained families.

Why this shot is different

WELTRUZA is the first and only once-monthly subcutaneous long-acting injectable formulation of olanzapine for adults with schizophrenia. Teva announced the approval on October 9, 2026, following the pivotal Phase 3 SOLARIS trial, and says it expects a U.S. launch in the coming weeks. It will come in three strengths: 318 mg, 425 mg, and 531 mg.

The detail that matters most is what it removes. For 17 years, the only long-acting olanzapine available required a certified facility, a three-hour observation period after each injection, and an escort home. Clinics had to build infrastructure around the drug. WELTRUZA eliminates all of that. Subcutaneous injection. No REMS program. No certified facility. No hours in a waiting room. No loading dose and no oral overlap while the drug ramps up. A quick shot during a regular visit, and the patient walks out.

The patients behind the numbers

“Olanzapine has been a trusted and foundational treatment option for people living with schizophrenia for more than 30 years, but adherence continues to be a major barrier to stability, particularly for those who rely on daily oral medications,” said Dr. Christoph Correll, clinical professor of psychiatry at the Zucker School of Medicine at Hofstra/Northwell, in Teva’s announcement. The new formulation, he said, can help empower patients, support their care partners, and give clinicians an important new tool for managing the condition.

The delivery system comes from Medincell, whose long-acting injectable technology releases medicine over weeks from a small, fully bioresorbable depot under the skin. This is the second U.S.-approved product from the Teva-Medincell partnership, following Uzedy, a long-acting injectable risperidone approved in 2023. Medincell may be eligible for up to $112 million in development and commercial milestone payments under the agreement, plus royalties on sales. Investors noticed: Teva shares closed 2% higher in Tel Aviv on the news, and Medincell jumped 16.9% in Paris.

What comes next

A European Marketing Authorization Application for the formulation was accepted by the EMA in May 2026, so a European decision may follow. Teva’s Chris Fox, executive vice president of U.S. Commercial, said the company developed the product “with the patient in mind from day one.” The real test will play out in clinics: how fast insurers cover it, how widely community psychiatrists adopt it, and whether the simplification translates into fewer relapses.

Reuters reported the approval on October 9, noting that analysts see long-acting formulations as a way to address treatment-adherence challenges in chronic psychiatric illness. That is the heart of this story. Schizophrenia is treatable, and has been for a long time. The barrier was never only the medicine – it was the daily ritual, the logistics, the hundred small frictions that stack up between a person and stability.

Sometimes the most important medical advances are not new molecules at all. They are new ways to make an old molecule do its job. A monthly shot cannot fix everything about schizophrenia. But it can fix the part where Tuesday’s forgotten pill becomes Thursday’s crisis. That is worth a great deal.